The case-fatality rate of meningococcal disease in Catalonia, 1990-1997

Scandinavian Journal of Infectious Diseases

Volumn 36, Issue 4, 2004, Pages 274-279

  Domínguez, Angela ^a,g   Cardeñosa, Neus ^a   Pañella, Helena ^b   Orcau, Angels ^c   Companys, Maria ^d   Alseda, Miquel ^e   Oviedo, Manuel ^a   Carmona, Glòria ^a   Minguell, Sofia ^f   Salleras, Lluis ^a   Curiel, G ^h   Dougan, M ^h   Escatllar, N ^h   Navarro, G ^h   Terrades, J ^h  

^a Directorate of Public Health   (Spain)

^b AGÈNCIA DE SALUT PÚBLICA DE BARCELONA   (Spain)

^c Territorial Delegation of Health   (Spain)

^d Territorial Delegation of Health   (Spain)

^e Territorial Delegation of Health   (Spain)

^f Territorial Delegation of Health   (Spain)

^g HOSPITAL CLÍNIC   (Spain)

^h NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ANAMNESIS; BACTERIAL MENINGITIS; BLOOD GROUP TYPING; CASE STUDY; CAUSE OF DEATH; CHILD; CLINICAL FEATURE; CONFIDENCE INTERVAL; DEMOGRAPHY; FATALITY; FEMALE; HUMAN; INFANT; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MENINGOCOCCOSIS; MULTIVARIATE ANALYSIS; NEISSERIA MENINGITIDIS; PHENOTYPE; RETROSPECTIVE STUDY; REVIEW; RISK ASSESSMENT; SEPTICEMIA; SPAIN; STRAIN DIFFERENCE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; BACTEREMIA; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INCIDENCE; INFANT; LOGISTIC MODELS; MALE; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL INFECTIONS; MIDDLE AGED; NEISSERIA MENINGITIDIS; SEX DISTRIBUTION; SPAIN; SURVIVAL ANALYSIS;

EID: 2642535449     PISSN: 00365548     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365540410020163     Document Type: Review

References (45)

1. Apicella MA. Neisseria meningitidis. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases. 5th ed. Philadephia: Churchill Livingstone; 2000. p. 2228-41.
2. Gold R. Neisseria meningitidis. In: Long SS, Pickering LK, Prober CG, eds. Principles and Practice of Pediatric Infectious Diseases. 2nd ed. New York: Churchill Livingstone; 2003. p. 748-56.
3. Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM. Meningococcal disease. N Engl J Med 2001; 344: 1378-88.
4. Van Deuren M, Brandtzaez P, Van der Meer JWM. Update on meningococcal disease with emphasis on pathogenesis and clinical management. Clin Microbiol Rev 2000; 13: 144-66.
5. Anonymous. The menigococcal disease in Galicia: season 1995-96. Bol Epidemiol Galicia 1996; 9: 1-4.
6. De Mateo Ontañón. The meningococcal disease in Spain, 1990-1997. Change in the epidemiological pattern. Rev Española Salud Públ 2000; 74: 387-96.
7. Selvin S. Epidemiologic analysis. Oxford: University Press; 2001. p. 145-60.
8. Hubert B, Goulet V, Riou JY. Surveillance of meningococcal disease in France, 1990-1997. Eurosurv 1997; 2: 78-9.
9. Ragunathan L, Ramsay M, Borrow R, Guiver M, Gray S, Kaczmarski B. Clinical features, laboratory findings and management of meningococcal meningitis in England and Wales: report of a 1997 survey of meningococcal meningitis. J Infect 2000; 40: 47-79.
10. Moura AS, Pablos-Mendez A, Layton M, Weiss D. Epidemiology of meningococcal disease, New York city, 1989-2000. Emerg Infect Dis 2003; 9: 355-61.
11. Pastor P, Medley FB, Murphy TV. Meningococcal disease in Dallas County, Texas: results of a 6-y population-based study. Ped Infect Dis J 2000; 19: 324-8.
12. Hasting L, Stuart J, Andrews N, Begg N. A retrospective survey of clusters of meningococcal disease in England and Wales, 1993 to 1995: estimated risks of further cases in household and educational settings. Comm Dis Report Rev 1997; 7: R195-200.
13. Jensen ES, Schonheyder HC, Lind I, Berthelsen L, Norgard B, Sorensen HT. Neisseria meningitidis phenotypic markers and septicaemia, disease progress and case-fatality rate of meningococcal disease: a 20-y population-based historical follow-up study in a Danish county J Med Microbiol 2003; 52: 173-9.
14. Fourquet F, Hubert B. Les infections a meningocoque en France en 1995. Bull Epidémiol Hebdom 1997; num. special: 22-24.
15. Jensen ES, Berthelsen L, Lind I, Fussing V, Sorensen HT, Schonheyder HC. Period prevalence and case-fatality rate associated with distinctive clone complexes of Neisseria meningitidis serogroups B and C. Europ J Clin Microbiol Infect Dis 2002; 21: 506-12.
16. Nelson RS, Morin CA, Cartter ML, Mshar P, Hadler JL, Beckett G, et al. Meningococcal disease. New England, 1993-1998. MMWR 1999; 48:629-33.
17. Schuchat A, Robinson K, Wenger JD, Harrison LH, Farley M, Reingold AL, et al. Bacterial meningitis in the United States in 1995. New Engl J Med 1997; 333: 970-6.
18. Spanjaard L, Bol P, de Marie S, Zanen HC. Association of meningococcal serogroups with the course of disease in the Netherlands 1959-83. Bull WHO 1987; 65: 861-8.
19. Barquet N, Domingo P, Cayla JA, Gonzalez J, Rodrigo C, Fernandez-Viladrich P, et al. Meningococcal disease in a large urban population (Barcelona, 1987-1992). Arch Int Med 1999; 159: 2329-39.
20. Sorensen HT, Nielsen GL, Schonheyder HC, Steffensen FH, Hansen I, Sabroe S, et al. Outcome of pre-hospital antibiotic treatment of meningococcal disease. J Clin Epidemiol 1998; 51: 717-21.
21. Norgard B, Sorensen HT, Jensen ES, Faber T, Schonheyder HC, Nielsen GL. Pre-hospital parenteral antibiotic treatment of meningococcal disease and case fatality: a Danish population-based cohort study. J Infect 2002; 45: 144-51.
22. Read RC, Camp NJ, di Giovine FS, Borrow R, Kaczmarski EB, Chaudhary AG, et al. An interleukin-1 genotype is associated with fatal outcome of meningococcal disease. J Infect Dis 2000; 182: 1557-60.
23. Westendorp RGJ, Langermans JAM, Huizinga TWJ, Elouali AH, Verweig CL, Boomsma DI, Vanderbrouke JP. Genetic influence of cytokine production and fatal meningococcal disease. Lancet 1997; 349: 170-3.
24. Riordan FA, Marzouk O, Thomson AP, Sills JA, Hart CA. Prospective validation of the Glasgow Meningococcal Septicaemia Prognostic Score. Comparison with other scoring methods. Eur J Ped 2002; 161: 531-7.
25. Harding D, Baines PB, Brull D, Vassiliou V, Ellis I, Hart A, et al. Severity of meningococcal disease in children and the angiotensin-converting enzyme insertion/deletion polymorphism. Am J Resp Crit Care Med 2002; 165: 1103-6.
26. Malley R, Huskins C, Kuppermann N. Multivariable predictive models for adverse outcome of invasive meningococcal disease in children. J Pediatr 1996; 129: 702-10.
27. Pollard AJ, Brittto J, Nadel S, DeMunter C, Habiti P, Levin M. Emergence management of meningococcal disease. Arch Dis Child 1999; 80: 290-6.
28. Spanjaard L, Bol P, de Marie S, Zanen HC. Association of meningococcal serotype with the course of disease: serotypes 2a and 2b in the Netherlands, 1959-1981. J Infect Dis 1987; 155: 277-82.
29. Palmer SR, Corson J, Hall R, Payne S, Ludlow J, Deere B, et al. Meningococcal disease in Wales: clinical features, outcome and public health management. J Infect 1992; 25: 321-8.
30. Squires SG, Pelletier L, Mungai M, Tsang R, Collins F, Stottz J. Invasive meningococcal disease in Canada, 1 January 1997 to 31 December 1998. Can Commun Dis Rep 2000; 26-21: 177-82.
31. Donalisio MR, Kemp B, Rocha MM, Ramalheira RM. CFR for meningococcal disease: study in the region of Campinas, SP, Brazil 1993 to 1998. Rev Saude Pub 2000; 34: 589-95.
32. Scholten RJPM, Bijlmer HA, Valkenburg HA, Dankert J. Patient and strain characteristics in relation to the outcome of meningococcal disease: a multivariate analysis. Epidemiol Infect 1994; 112: 115-24.
33. Rosenstein NE, Perkins BA, Stephens DS, Lefkowitz L, Cartter ML, Danila R, et al. The changing epidemiology of meningococcal disease in the United States, 1992-1996. J Infect Dis 1999; 18: 1894-901.
34. Booy R, Habibi P, Nadel S, de Munter C, Britto J, Morrison A, Levin M. Meningococcal Research Group. Reduction in case fatality rate from meningococcal disease associated with improved healthcare delivery. Arch Dis Child 2001; 85: 386-90.
35. Roznovsky L, Krizova P, Struncova V, Dostal V, Plisek S, Kasal E, et al. Administration of antibiotics before admission in patients with meningococcal disease. Cent Eur J Public Health 2003; 11: 14-8.
36. El Bushra HE, Hassan NM, Al-Hamdan NA, Al-Jeffri MH, Turkistani AM, Al-Jumaily A, et al. Determinants of CFRs of meningococcal disease during outbreaks in Makkah, Saudi Arabic, 1987-97. Epidemiol Infect 2000; 125: 555-60.
37. Erickson L, De Wals P. Complications and sequelae of meningococcal disease in Quebec, Canada, 1990-1994. Clin Infect Dis 1998; 26: 1159-64.
38. Ward J, Hanna JN, Bates JR, Selvey LA. Enhanced surveillance for meningococcal disease in Queensland in 1999. Commun Dis Intell 2000; 24: 332-5.
39. Salleras L, Dominguez A, Prats G, Ramon I, Muñoz P. Dramatic decline of serogroup C meningococcal disease incidence in Catalonia (Spain) 24 months after a mass vaccination programme of children and young people. J Epidemiol Commun Health 2001; 55: 283-877.
40. Salleras L, Dominguez A, Cardeñosa N. Dramatic decline of serogroup C meningococcal disease in Catalonia (Spain) after a mass vaccination campaign with meningococcal C conjugated vaccine. Vaccine 2003; 21: 729-33.
41. Cartwright K, Morris R, Rümke H, Fox A, Borrow R, Begg N, et al. Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (Por A) outer membrane proteins. Vaccine 1999; 17: 2612-9.
42. Pizza M, Scarlato V, Masignani V, Giuliani MM, Arico B, Comanducci M, et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 2000; 287: 1816-20.
43. Barroso DE, Carvalho DM, Netto MA, Santos OH, Nascimento FA, Werneck GL. The effect of subcapsular meningococcal B+C vaccine on the prognosis of patients with meningococcal disease. Scand J Infect Dis 2002; 34: 417-20.
44. Claassen I, Meylis J, van der Ley P, Peeters C, Brons H, Robert J, et al. Production, characterization and control of a Neisseria meningitidis hexavalent class 1 outer membrane protein containing vesicle vaccine. Vaccine 1996; 14: 1001-8.
45. De Kleijn E, van Eijndhoven L, Vermont C, Kuipers B, van Dijken H, Rumke H, et al. Serum bactericidal activity and isotype distribution of antibodies in toddlers and schoolchildren after vaccination with RIVM hexavalent PorA vesicle vaccine. Vaccine 2001; 20: 352-8.